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Colorectal cancer (CRC) can arise through several different biological pathways, which can be 
characterized by different combinations of genetic and epigenetic changes within the tumor.  These 
different pathways may influence tumor characteristics, such as cancer aggressiveness, which in 
turn can affect patient survival following diagnosis and treatment.  While previous studies have 
considered various markers of tumor characteristics by themselves, a more comprehensive 
evaluation of the association of molecular subtypes for CRC survival was needed.  In a recent report 
in Gastroenterology, Drs. Amanda Phipps and Polly Newcomb, together with colleagues in the 
Public Health Sciences Division, combined four molecular tumor markers to evaluate five different 
CRC subtypes, and found marked differences in survival. 
The motivation for this study came from recent successes in personalized and precision medicine in 
other areas of oncology.  "Over the past few decades," said lead author Dr. Phipps, "we've seen 
leaps forward in terms of the development and availability of targeted cancer therapies - therapies 
that allow us to more effectively treat different patients with different subtypes of a given 
cancer.  Still, there is very little in the way of targeted treatment options for patients with colorectal 
cancer."  By demonstrating that differences exist between CRC subtypes, the authors hope to 
encourage the development of personalized treatment therapies that can improve outcomes for this 
common cancer. 
To evaluate these CRC subtypes, the authors evaluated over 2,000 paraffin-embedded formalin-
fixed diagnostic tumor tissue specimens from participants in two Seattle-based studies: the Seattle 
Colon Cancer Family Registry and the Postmenopausal Hormones Supplemental Study to the 
Seattle Colon Cancer Family Registry.  These tumor samples were then assessed for each of four 
molecular characteristics that reflect different molecular changes in the tumor: microsatellite 
instability status (MSI; stable/low/high), BRAF V600E mutation (yes/no), KRAS codon 12 or 13 
mutation (yes/no), and CpG island methylator phenotype status (CIMP; positive/negative).  Each 
tumor was then classified into one of five tumor types according to the combination of these four 
subtypes (see figure). 
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Using outcomes data obtained from linkages to the SEER cancer registry (Surveillance, 
Epidemiology, and End Results program) and the National Death Index, the authors then evaluated 
the association between these CRC subtypes and both overall and CRC-specific 
survival.  Compared to type 4, the most common subtype of CRC, the authors found that the 
mortality rates were higher for subtypes 2 and 3 and lower for subtypes 1 and 5.  The highest CRC-
specific mortality was found for type 2 tumors (hazard ratio = 2.20, 95% confidence interval = 1.47 - 
3.31), while type 5 tumors had the lowest CRC-specific mortality (hazard ratio = 0.30, 95% 
confidence interval = 0.14 - 0.66).  Associations with overall mortality were attenuated but similar.  
Together, these findings suggest a complex interplay between these molecular markers, tumor 
subtype, and survival outcomes.  "Our results illustrate that not all colorectal cancers are created 
equal," said Dr. Phipps.  "There are dramatic differences in the survival outlook for patients with the 
different colorectal cancer subtypes we explored.  We hope these survival differences will motivate 
and guide the development of more targeted treatment options for patients with colorectal cancer." 
Now that survival differences by CRC subtype have been identified, the next step will be to study the 
biological mechanisms that drive these differences.  "Although we can very clearly see differences in 
survival across the subtypes of colorectal cancer we evaluated, what is driving these differences is 
not yet clear," said Dr. Phipps.  "We would like to better understand how these different tumor 
subtypes differ in terms of their responsiveness to cancer therapies, how often (and when and 
where) they metastasize, and how patients with these different subtypes of disease differ in terms of 
their lifestyle patterns and underlying health.  We’ve identified a pattern - the next step is to 
understand the basis for that pattern." 
Other PHS investigators contributing to this project were Drs. Andrea Burnett-Hartman and John 
Potter. 
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Image provided by Dr. Amanda Phipps 
Kaplan-Meier survival curves showing the disease-specific 
survival of colorectal cancer patients by molecular subtype, as 
defined by the status of four molecular markers: microsatellite 
instability (MSI), BRAF, KRAS, and CpG island methylator 
phenotype (CIMP). 
 
 
